Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

A mentation of this nonfiction archetypal appeared successful CNBC's Healthy Returns newsletter, which brings the latest health-care quality consecutive to your inbox. Subscribe here to person aboriginal editions.

After the motorboat of the first-ever GLP-1 pill for value nonaccomplishment from Novo Nordisk this month, obesity was apical of caput astatine the yearly JPMorgan Healthcare Conference, which drew thousands of pharma and biotech companies, investors, advisors and analysts.

I sat down with Ray Stevens, the CEO of obesity marketplace hopeful Structure Therapeutics, astir the biotech's way guardant and his expectations for the aboriginal of the booming GLP-1 space. 

It's a large twelvemonth for Structure, arsenic the company's regular oral GLP-1 is slated to participate signifier 3 trials. Shares of Structure soared much than 100% connected Dec. 9 aft it released midstage information showing that its pill, aleniglipron, helped patients with obesity suffer much than 11% of their value astatine 36 weeks, erstwhile adjusted for placebo.

Here are immoderate highlights from my interrogation with Stevens astatine the conference. 

Stevens said 2026 is each astir preparing for the signifier 3 trials connected aleniglipron. He said helium believes Novo Nordisk's now-approved pill and an upcoming rival oral cause from Eli Lilly volition person beardown launches, and that Structure's pill is "next successful line" to participate the market. 

"I deliberation we'll person truly bully tailwinds going into that with a perchance best-in-class medicine," helium told CNBC. 

Stevens said he's arrogant of the information that came retired connected the cause successful December, touting its "really bully efficacy" and tolerability, oregon information connected however good patients tolerated the treatment. In the signifier 2 trial, determination were nary discontinuations owed to broadside effects among patients who started the cause astatine a debased dose of 2.5 milligrams.

Stevens said determination are 4 reasons. 

First, efficacy. The signifier 2 proceedings successful December showed that a higher, 240-milligram dose helped patients suffer up to 15.3% of their value astatine 36 weeks, erstwhile adjusted for placebo. 

Stevens said different competitors are reporting that level of value nonaccomplishment aft a longer clip period, specified arsenic 60 to 72 weeks. 

Safety is different factor, helium added. For example, Structure observed nary drug-related liver injuries crossed studies connected the pill – an contented that dogged different experimental oral obesity treatments. 

Stevens said the 3rd crushed is the comparatively debased outgo of manufacturing the pill, which is simply a small-molecule drug. 

"We person the quality to standard astatine a precise ample scale, and truthful we tin proviso the full U.S. marketplace easily," helium said. 

The 4th factor, helium said, is that Structure's pill is combinable. 

The institution released information showing that it tin brace its oral GLP-1 with its different cause targeting the amylin gut hormone and execute "really synergistic effects," Stevens said. He added that an oral GLP-1 tin beryllium combined with different types of treatments, specified arsenic PCSK9 inhibitors, oregon drugs that drastically little "bad" LDL cholesterol. 

"Aleniglipron is precise combinable with different medicines, truthful we're excited," Stevens said. 

Oral drugs could grow the market, Stevens said. He noted that 100 cardinal radical successful the U.S. request attraction for obesity but lone astir 5 cardinal are receiving the existing injections. 

The "real growth" and uptake of the pills is going to travel from superior attraction physicians, who constitute the bulk of prescriptions for Americans, Stevens said. 

Those doctors similar pills for their flexibility, helium added. 

Stevens said helium has seen cases wherever patients taking the injections acquisition broadside effects and "are conscionable truly unhappy for a week and they volition not get adjacent that needle ever again." But regular pills tin marque it easier to instrumentality the drugs. 

For example, helium said a diligent could chopped a pill successful fractional to mitigate broadside effects connected a time wherever they person an important gathering to attend. 

Stevens said helium believes combinations are "going to beryllium the adjacent signifier of the field."

"I consciousness similar the winners are present starting to look for the monotherapy" treatments, helium said. But Stevens said the diligent colonisation volition conception according to the different wellness conditions a idiosyncratic has connected apical of obesity, specified arsenic fatty liver disease, chronic kidney illness and cardiovascular disease. 

That's wherever combinations tin travel in, helping dainty a information amended than 1 merchandise alone. 

Looking further into the future, Stevens said helium hopes that entree and affordability are nary longer an contented successful the space. The marketplace has made strides implicit the past year. Novo Nordisk and Eli Lilly are cutting currency prices for their injections and upcoming pills, portion Medicare sum for obesity drugs volition commencement aboriginal this year. 

Stevens said helium is "okay with the outgo dropping due to the fact that to me, this has ever been astir measurement and truly trying to code a precise ample unmet request globally." 

He said helium besides hopes patients volition person much attraction options successful the future, whether that is simply a once-monthly injectable oregon antithetic kinds of pills.

Feel escaped to nonstop immoderate tips, suggestions, communicative ideas and information to Annika astatine a caller email: annika.constantino@versantmedia.com.